RT Journal Article
SR Electronic
T1 A meta-analysis of the genome-wide association studies on two genetically correlated phenotypes (self-reported headache and self-reported migraine) identifies four new risk loci for headaches (N=397,385)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21263668
DO 10.1101/2021.09.15.21263668
A1 Meng, Weihua
A1 Reel, Parminder S
A1 Nangia, Charvi
A1 Rajendrakumar, Aravind Lathika
A1 Hebert, Harry L
A1 Adams, Mark J
A1 Zheng, Hua
A1 Lu, Zen Haut
A1 ,
A1 Ray, Debashree
A1 Colvin, Lesley A
A1 Palmer, Colin NA
A1 McIntosh, Andrew
A1 Smith, Blair H
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.15.21263668.abstract
AB Headache is one of the commonest complaints that doctors need to address in clinical settings. The genetic mechanisms of different types of headache are not well understood. In this study, we performed a meta-analysis of genome-wide association studies (GWAS) on the self-reported headache phenotype from the UK Biobank cohort and the self-reported migraine phenotype from the 23andMe resource using the metaUSAT for genetically correlated phenotypes (N=397,385). We identified 38 loci for headaches, of which 34 loci have been reported before and 4 loci were newly identified. The LRP1-STAT6-SDR9C7 region in chromosome 12 was the most significantly associated locus with a leading P value of 1.24 × 10−62 of rs11172113. The ONECUT2 gene locus in chromosome 18 was the strongest signal among the 4 new loci with a P value of 1.29 × 10−9 of rs673939. Our study demonstrated that the genetically correlated phenotypes of self-reported headache and self-reported migraine can be meta-analysed together in theory and in practice to boost study power to identify more new variants for headaches. This study has paved way for a large GWAS meta-analysis study involving cohorts of different, though genetically correlated headache phenotypes.Competing Interest StatementThe employees of 23andMe/23andMe Research Team hold stock in the company. The other authors declare that they have no conflict of interest.Funding StatementThis work was supported by the STRADL project [Wellcome Trust, grant number: 104036/Z/14/Z]. The funders had no role in study design, data collection, data analysis, interpretation, writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was conducted under approved UK Biobank data application number 4844.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GWAS meta-analysis summary statistics can be downloaded from https://app.box.com/s/gm2qkf17hc9w1fc5ymvifgbxz0httvhs The FUMA results can be viewed from https://fuma.ctglab.nl/browse/334. Data from 23andMe were obtained under a data transfer agreement. Further information about obtaining access to the 23andMe Inc. summary statistics is available from: https://research.23andme.com/collaborate/. Any other data relevant to the study that are not included in the article or its supplementary materials are available from the authors upon reasonable request. https://app.box.com/s/gm2qkf17hc9w1fc5ymvifgbxz0httvhs